Literature DB >> 2836804

Reduced DNA topoisomerase II activity in ataxia-telangiectasia cells.

S P Singh1, R Mohamed, C Salmond, M F Lavin.   

Abstract

Considerable evidence supports a defect at the level of chromatin structure or recognition of that structure in cells from patients with the human genetic disorder ataxia-telangiectasia. Accordingly, we have investigated the activities of enzymes that alter the topology of DNA in Epstein Barr Virus-transformed lymphoblastoid cells from patients with this syndrome. Reduced activity of DNA topoisomerase II, determined by unknotting of P4 phage DNA, was observed in partially purified extracts from 5 ataxia-telangiectasia cell lines. The levels of enzyme activity was reduced substantially in 4 of these cell lines and to a lesser extent in the other cell line compared to controls. DNA topoisomerase I, assayed by relaxation of supercoiled DNA, was found to be present at comparable levels in both cell types. Reduced activity of topoisomerase II in ataxia-telangiectasia is compatible with the molecular, cellular and clinical changes described in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836804      PMCID: PMC336565          DOI: 10.1093/nar/16.9.3919

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  35 in total

1.  ATAXIA-TELANGIECTASIA. ITS ASSOCIATION WITH A DEFECTIVE THYMUS, IMMUNOLOGICAL-DEFICIENCY DISEASE, AND MALIGNANCY.

Authors:  R D PETERSON; W D KELLY; R A GOOD
Journal:  Lancet       Date:  1964-05-30       Impact factor: 79.321

2.  Defective excision repair of gamma-ray-damaged DNA in human (ataxia telangiectasia) fibroblasts.

Authors:  M C Paterson; B P Smith; P H Lohman; A K Anderson; L Fishman
Journal:  Nature       Date:  1976-04-01       Impact factor: 49.962

3.  Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity.

Authors:  A M Taylor; D G Harnden; C F Arlett; S A Harcourt; A R Lehmann; S Stevens; B A Bridges
Journal:  Nature       Date:  1975-12-04       Impact factor: 49.962

4.  Cytogenetic investigations in families with ataxia-telangiectasia.

Authors:  M M Cohen; M Shaham; J Dagan; E Shmueli; G Kohn
Journal:  Cytogenet Cell Genet       Date:  1975

5.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

6.  Ataxia-telangiectasia.

Authors:  D E McFarlin; W Strober; T A Waldmann
Journal:  Medicine (Baltimore)       Date:  1972-07       Impact factor: 1.889

7.  Identification of ataxia telangiectasia heterozygotes, a cancer prone population.

Authors:  P C Chen; M F Lavin; C Kidson; D Moss
Journal:  Nature       Date:  1978-08-03       Impact factor: 49.962

8.  High frequencies of inversions and translocations of chromosomes 7 and 14 in ataxia telangiectasia.

Authors:  A Aurias; B Dutrillaux; D Buriot; J Lejeune
Journal:  Mutat Res       Date:  1980-02       Impact factor: 2.433

9.  Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells.

Authors:  J Houldsworth; M F Lavin
Journal:  Nucleic Acids Res       Date:  1980-08-25       Impact factor: 16.971

10.  The rate of DNA synthesis in normal human and ataxia telangiectasia cells after exposure to X-irradiation.

Authors:  J de Wit; N G Jaspers; D Bootsma
Journal:  Mutat Res       Date:  1981-01       Impact factor: 2.433

View more
  2 in total

1.  Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.

Authors:  S M Davies; A L Harris; I D Hickson
Journal:  Nucleic Acids Res       Date:  1989-02-25       Impact factor: 16.971

2.  Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.

Authors:  J M Cunningham; G E Francis; M J Holland; K F Pirollo; E H Chang
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.